Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 10 March 2006. doi:10.1136/bjo.2005.088278
British Journal of Ophthalmology 2006;90:705-708
Copyright © 2006 by the BMJ Publishing Group Ltd.

SCIENTIFIC REPORT

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye

B R Kosobucki, W R Freeman and L Cheng

Joan and Irwin Jacobs Retina Center, Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, 9415 Campus Point Drive, La Jolla, CA 92093-0946, USA

Correspondence to:
Correspondence to:
William R Freeman
MD, Joan and Irwin Jacobs Retina Center, Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, 9415 Campus Point Drive, La Jolla, CA 92093-0946, USA; freeman{at}eyecenter.ucsd.edu

ABSTRACT

Aim: To determine the duration of residence of triamcinolone in the vitrectomised eye.

Methods: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with macular oedema from diabetes, uveitis, cataract surgery, or other surgery.

Results: The median time to disappearance of triamcinolone in the vitrectomised eye was 113 days (95% confidence interval (CI) 85 to 191). In the phakic eyes the median time to disappearance was 191 days (95% CI 148 to 191). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85 to 113). This difference was not significant (p = 0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced intraocular pressure rise >=10 mm Hg.

Conclusions: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomised eye. Although this appears to be shorter than in the non-vitrectomised eye, this study suggests that a sufficient duration of action will be present to be clinically useful.

Abbreviations: ARMD, age related macular degeneration; IOP, intraocular pressure; POAG, primary open angle glaucoma

Keywords: diabetes; macular degeneration; macular oedema; triamcilone; vitreous injection


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

BJO at a glance
Creig Hoyt
Br. J. Ophthalmol. 2006 90: 663. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Tammewar, A M, Cheng, L, Kayikcioglu, O R, Falkenstein, I A, Kozak, I, Goldbaum, M H, Freeman, W R (2008). Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br. J. Ophthalmol. 92: 810-813 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Ophthalmology Jobs

Ophthalmology Jobs